Nurix Therapeutics Files 8-K

TL;DR

Nurix Therapeutics filed an 8-K on 4/9/24, updating corporate info. Nothing major.

AI Summary

Nurix Therapeutics, Inc. filed an 8-K on April 9, 2024, reporting other events and financial statements. The filing details the company's principal executive offices located at 1700 Owens Street, Suite 205, San Francisco, CA 94158, and its telephone number (415) 660-5320. The company was incorporated in Delaware and its fiscal year ends on November 30.

Why It Matters

This 8-K filing provides updated corporate information and signals ongoing regulatory compliance for Nurix Therapeutics, Inc.

Risk Assessment

Risk Level: low — This filing is a routine corporate update and does not contain material non-public information that would significantly impact the company's risk profile.

Key Players & Entities

• Nurix Therapeutics, Inc. (company) — Registrant
• April 9, 2024 (date) — Date of Report
• 1700 Owens Street, Suite 205 (address) — Principal Executive Offices
• San Francisco, California (location) — Principal Executive Offices Location
• 94158 (zip_code) — Principal Executive Offices Zip Code
• (415) 660-5320 (phone_number) — Registrant's Telephone Number
• Delaware (location) — State of Incorporation
• November 30 (date) — Fiscal Year End

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value per share NRIX Nasdaq Global

Filing Documents

• nrix-20240409.htm (8-K) — 29KB
• 0001549595-24-000041.txt ( ) — 154KB
• nrix-20240409.xsd (EX-101.SCH) — 2KB
• nrix-20240409_lab.xml (EX-101.LAB) — 22KB
• nrix-20240409_pre.xml (EX-101.PRE) — 13KB
• nrix-20240409_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On April 9, 2024, Nurix Therapeutics, Inc. (Nurix) announced the presentation of the first findings of clinical responses in the brain for NX-5948, an orally available, selective degrader of Bruton's tyrosine kinase (BTK) currently under evaluation in a Phase 1a/1b clinical trial in patients with relapsed or refractory B cell malignancies. The presentation included case studies for two patients, one with chronic lymphocytic leukemia (CLL) with central nervous system (CNS) involvement and the other with primary central nervous system lymphoma (PCNSL), each demonstrating clinically meaningful responses. The case studies were presented by Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix, as part of the Major Symposium session Molecular Glues, PROTACs, and Next-Gen Degraders: Discovery and Early Preclinical Advances at the American Association for Cancer Research 2024 Annual Meeting, which is being held from April 5-10, 2024, in San Diego, CA. The presentation included data demonstrating the detection of NX-5948 in the cerebrospinal fluid (CSF) from all patients with available CSF samples. The case studies were from two of these patients. In one case study, a CLL patient was enrolled with secondary CNS involvement whose disease progressed following three prior lines of treatment, including both a BCL2 inhibitor in combination with rituximab and a BTK inhibitor (acalabrutinib). This patient, who presented with malignant cells in the CSF at study entry and the high-risk cytogenetic marker Del17p, received NX-5948 at a once daily dose of 100 mg. By week 8, the patient had significant lymph node reduction and spleen reduction consistent with stable disease. By week 16, the patient had experienced continued reduction in lymph nodes and spleen size and improvements in hematologic measures consistent with a partial response. By week 24, the partial response was confirmed and the patient no longer had measurable tumor cells in the CSF. As

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are filed herewith and this list is intended to constitute the exhibit index: Exhibit No. Exhibit Title or Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NURIX THERAPEUTICS, INC. Date: April 9, 2024 By: /s/ Christine Ring Christine Ring, Ph.D., J.D. Chief Legal Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR